Literature DB >> 2938706

Restenosis following percutaneous transluminal angioplasty: clinical, physiologic and pathological features.

J L Cox, A I Gotlieb.   

Abstract

Percutaneous transluminal coronary angioplasty (PTCA) has been used clinically for 8 years and is becoming widely accepted in the treatment of atherosclerotic coronary artery disease. Since the long-term effects of the procedure are unknown, the rate of restenosis following the procedure, approximately 30%, is of major concern. We briefly review the current status of PTCA and the effect of angioplasty on the vessel wall and discuss proposed mechanisms of recurrent stenosis.

Entities:  

Mesh:

Year:  1986        PMID: 2938706      PMCID: PMC1491035     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  32 in total

1.  The anatomic evolution of coronary artery disease demonstrated by coronary arteriography in 256 nonoperated patients.

Authors:  A V Bruschke; T S Wijers; W Kolsters; J Landmann
Journal:  Circulation       Date:  1981-03       Impact factor: 29.690

2.  Should coronary arteries with less than 60% diameter stenosis be treated by angioplasty?

Authors:  T Ischinger; A R Gruentzig; J Hollman; S King; J Douglas; B Meier; J Bradford; R Tankersley
Journal:  Circulation       Date:  1983-07       Impact factor: 29.690

3.  Thrombin generation and fibrin formation following injury to rabbit neointima. Studies of vessel wall reactivity and platelet survival.

Authors:  H M Groves; R L Kinlough-Rathbone; M Richardson; L Jørgensen; S Moore; J F Mustard
Journal:  Lab Invest       Date:  1982-06       Impact factor: 5.662

4.  Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study.

Authors:  M A Thornton; A R Gruentzig; J Hollman; S B King; J S Douglas
Journal:  Circulation       Date:  1984-04       Impact factor: 29.690

5.  Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty.

Authors:  G E Austin; N B Ratliff; J Hollman; S Tabei; D F Phillips
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

6.  Percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris: analysis of early and late results.

Authors:  J Meyer; H J Schmitz; T Kiesslich; R Erbel; W Krebs; W Schulz; P Bardos; C Minale; B J Messmer; S Effert
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

7.  The mechanism of transluminal angioplasty: evidence for formation of aneurysms in experimental atherosclerosis.

Authors:  T A Sanborn; D P Faxon; C Haudenschild; S B Gottsman; T J Ryan
Journal:  Circulation       Date:  1983-11       Impact factor: 29.690

8.  Smooth muscle and endothelial cell function in the pathogenesis of atherosclerosis.

Authors:  A I Gotlieb
Journal:  Can Med Assoc J       Date:  1982-04-15       Impact factor: 8.262

9.  Status of the major epicardial coronary arteries 80 to 150 days after percutaneous transluminal coronary angioplasty. Analysis of 3 necropsy patients.

Authors:  B F Waller; B M McManus; H J Gorfinkel; J C Kishel; E C Schmidt; K M Kent; W C Roberts
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

10.  Arterial disruption and remodeling following balloon dilatation.

Authors:  C K Zarins; C T Lu; B L Gewertz; R T Lyon; D S Rush; S Glagov
Journal:  Surgery       Date:  1982-12       Impact factor: 3.982

View more
  4 in total

1.  The Strecker stent: indications and results in iliac and femoropopliteal arteries.

Authors:  D Liermann; E P Strecker; J Peters
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Sep-Oct       Impact factor: 2.740

2.  [Endovascular Ir-192 HDR brachytherapy for avoidance of intimal hyperplasia in peripheral vessels after PTA and stent implantation. A 6-year experience].

Authors:  H D Böttcher; B Schopohl
Journal:  Strahlenther Onkol       Date:  1998-03       Impact factor: 3.621

3.  Iliac and femoropopliteal vascular occlusive disease treated with flexible tantalum stents.

Authors:  E P Strecker; B Hagen; D Liermann; B Schneider; H R Wolf; J Wambsganss
Journal:  Cardiovasc Intervent Radiol       Date:  1993 May-Jun       Impact factor: 2.740

4.  Brachytherapy with iridium-192 HDR to prevent from restenosis in peripheral arteries. An update.

Authors:  D Liermann; J Kirchner; R Bauernsachs; B Schopohl; H D Böttcher
Journal:  Herz       Date:  1998-09       Impact factor: 1.443

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.